MediWound Q1 Revenue Misses by Over 50%, Citing BARDA Timing and Conflict
MDWD is trading near its 52-week low of $14.9 (12% above the low).
Summary
MediWound reported Q1 revenue of $1.5 million, significantly missing analyst expectations of $3.12 million. The company attributed the miss primarily to the timing of BARDA-related revenues and postponed shipments due to regional conflict. Despite the Q1 shortfall, MediWound reaffirmed its full-year 2026 revenue guidance of $24-26 million and beat adjusted EBITDA estimates. While the revenue miss is substantial, the reaffirmed full-year guidance and positive EBITDA suggest the Q1 performance may be an anomaly rather than a systemic issue. Investors will be looking for initial NexoBrid BARDA procurement activity in the second half of 2026 to validate the company's outlook.
At the time of this announcement, MDWD was trading at $16.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $214.3M. The 52-week trading range was $14.90 to $22.51. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.